| Trial ID | NCT06381791 |
| Phase | N/A |
| Status | Recruiting |
| Condition | Shoulder Osteoarthritis |
| Intervention | Epidiolex |
Post-operative pain management remains a significant challenge, with many patients requiring opioids that carry addiction risks. This trial addresses whether pharmaceutical-grade CBD can serve as an effective adjunct analgesic in the acute post-surgical period, potentially reducing opioid requirements.
This placebo-controlled trial is evaluating Epidiolex (pharmaceutical CBD) as adjunctive pain management following orthopedic shoulder surgery in patients with shoulder osteoarthritis. Participants maintain daily pain diaries, undergo weekly researcher check-ins, complete pre- and post-operative surveys, and provide blood samples for pharmacokinetic analysis. The study is currently recruiting and focuses on both efficacy and safety endpoints including optimal dosing parameters.
โIf positive, this could provide the first rigorous evidence for CBD’s role in acute post-operative pain, giving me a validated tool to potentially reduce my patients’ opioid exposure during their most vulnerable recovery period.โ
๐ฌ Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan โ
Want to discuss this topic with other patients and caregivers? Join the forum discussion โ
Have thoughts on this? Share it: